Older AML Treatment: New Insights From ASH! | Ira Zackon, MD

Bleximenib Breakthrough in High-Risk AML? | Hartmut Döhner, MD

Less Invasive AML & MDS Monitoring: Blood Tests & Machine Learning | Lisa Pleyer, MD

Real‑World Results for Menin Inhibitors in Hard‑to‑Treat AML | Kuo-Kai Chin, MD

MECOM Rearrangements in AML: What Patients Need to Know | Jesus Gonzales Lugo, MD

Can Nadir Bone Marrow Predict AML Outcomes? New Trial Data | Douglas Tremblay, MD

Is the Blexi‑Ven Combo Safe and Effective? | Jenny O'Nions, MD

Hypomethylating agent for newly diagnosed TP53-mutant AML | Talher Badar, MBBS, MD

Improving Outcomes in FLT3-mutant AML: Crenolanib + Chemo | Thomas Cluzeau, MD, PhD

How is graft vs host disease (GVHD) minimized and managed?

How is multidisciplinary care used for graft vs host disease (GVHD)?

What types of transplants are patients more likely to experience graft vs host disease (GVHD)?

What are the biggest challenges children face during recovery, and how can they be managed?

 What are the long term effects of transplant, and what type of follow up care is needed?